Combination Treatment with Cold Physical Plasma and Pulsed Electric Fields Augments ROS Production and Cytotoxicity in Lymphoma

• Published in: Cancers Vol. 12; no. 4; p. 845
• Main Authors: Wolff, Christina M, Kolb, Juergen F, Weltmann, Klaus-Dieter, von Woedtke, Thomas, Bekeschus, Sander
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.03.2020; MDPI
• Subjects: Antioxidants; Apoptosis; Caspase; Cell cycle; Cell death; Cell membranes; Chemotherapy; Cytotoxicity; Electric fields; Ferroptosis; Flow cytometry; Lipid peroxidation; Lipids; Lymphoma; Metabolism; Mitochondria; Plasma; Quantitative analysis; Reactive oxygen species; Supplements; Tumor cell lines; PEF; plasma medicine; reactive oxygen and nitrogen species
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12040845

New approaches in oncotherapy rely on the combination of different treatments to enhance the efficacy of established monotherapies. Pulsed electric fields (PEFs) are an established method (electrochemotherapy) for enhancing cellular drug uptake while cold physical plasma is an emerging and promising anticancer technology. This study aimed to combine both technologies to elucidate their cytotoxic potential as well as the underlying mechanisms of the effects observed. An electric field generator (0.9-1.0 kV/cm and 100-μs pulse duration) and an atmospheric pressure argon plasma jet were employed for the treatment of lymphoma cell lines as a model system. PEF but not plasma treatment induced cell membrane permeabilization. Additive cytotoxicity was observed for the metabolic activity and viability of the cells while the sequence of treatment in the combination played only a minor role. Intriguingly, a parallel combination was more effective compared to a 15-min pause between both treatment regimens. A combination effect was also found for lipid peroxidation; however, none could be observed in the cytosolic and mitochondrial reactive oxygen species (ROS) production. The supplementation with either antioxidant, a pan-caspase-inhibitor or a ferroptosis inhibitor, all partially rescued lymphoma cells from terminal cell death, which contributes to the mechanistic understanding of this combination treatment.